On June 30, 2021, the clinical trialÂ NCT03151239, titled Effect ofÂ “Nicotinamide Mononucleotide” (NMN) on Cardiometabolic Function, was completed. The safety and effect of 250 mg of NMN for at least eight weeks on essential cardiovascular and metabolic functions of 25 post-menopausal pre-diabetic women were examined. This included an analysis of risk factors for diabetes and cardiovascular disease. The investigators evaluated NMNâ€™s effects on insulin’s ability to control blood sugar. Investigators also looked at the effects of NMN on blood lipids, body and liver fat, and other blood, fat tissue, and muscle tissue markers of cardiovascular (heart) and metabolic health. The study showed that NMN improved the ability of insulin to increase glucose uptake in skeletal muscle, which often is abnormal in people with obesity, prediabetes or Type 2 diabetes. NMN also improved expression of genes that are involved in muscle structure and remodeling. However, the treatment did not lower blood glucose or blood pressure, improve blood lipid profile, increase insulin sensitivity in the liver, reduce fat in the liver or decrease circulating markers of inflammation as seen in mice.Â The authors stated that more studies are needed to determine whether NMN has beneficial effects in the prevention or management of prediabetes or diabetes in people.